Mid-Atlantic BioTherapeutics (MABT) Email Format

Biotechnology ResearchPennsylvania, United States2-10 Employees

Mid-Atlantic BioTherapeutics (MABT) is a biotechnology research company focused on developing immunotherapy approaches to infectious diseases. Its lead platform, IMT504, engages the body's immune system to address infections that are difficult to treat with conventional therapies, with activity demonstrated in animal models and early human data. The company positions itself within the clinical-stage pharmaceutical space, aiming to address antibiotic resistance and to explore treatments for viral diseases, emerging infections, and biodefense, including regulatory incentives such as Orphan Drug Designation for late-stage rabies disease. Based in Doylestown, Pennsylvania, MABT was founded in 2011 and operates with a small team dedicated to advancing its immunotherapy programs and potential collaborations in infectious disease applications. Recent developments include strategic expansions and partnerships, including the integration of XPose Therapeutics and a facility expansion in Asia to support research and production activities.

Get verified Mid-Atlantic BioTherapeutics (MABT) emails free

Company overview Employee directory